Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 6/20 | 0.38 |
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.34 |
| ▸ | ABL1 | P00519 | 3/20 | 0.34 |
| ▸ | DEGS1 | O15121 | 2/20 | 0.33 |
| ▸ | F10 | P00742 | 2/20 | 0.32 |
| ▸ | F2 | P00734 | 1/20 | 0.32 |
| ▸ | F5 | P12259 | 1/20 | 0.32 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4954432 | 0.90 | RAB9A (0.43) | OPRM1OPRL1 | |
| SCHEMBL1504138 | 0.89 | L3MBTL1 (0.42) | F10F2F5 | |
| SCHEMBL4955316 | 0.82 | KCNQ3 (0.36) | F10 | |
| SCHEMBL1503995 | 0.80 | L3MBTL1 (0.44) | F10F2F5 | |
| SCHEMBL12101136 | 0.77 | F10 (0.39) | GRM5CYP46A1OPRM1OPRL1DEGS1 | |
| SCHEMBL4260523 | 0.77 | L3MBTL1 (0.41) | F10F2F5 | |
| SCHEMBL1504053 | 0.77 | F10 (0.43) | GRM5CYP46A1ABL1F10F2 | |
| SCHEMBL2941002 | 0.77 | F10 (0.43) | GRM5CYP46A1ABL1F10F2 | |
| Hydrochloric Acid SCHEMBL3305337 | 0.77 | F10 (0.38) | GRM5CYP46A1OPRM1OPRL1DEGS1 | |
| SCHEMBL6891046 | 0.76 | PRMT5 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110312990-A1 | Diamine Derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-12-22 | — | — | US | disclosed |
| EP-2343290-A1 | Diamine derivatives as factor X inhibitors | Daiichi Sankyo Company, Limited (JP) | 2011-07-13 | — | — | EP | disclosed |
| US-20110077266-A1 | Diamine Derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-03-31 | — | — | US | disclosed |
| US-7342014-B2 | Diamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2008-03-11 | — | — | US | disclosed |
| US-20050245565-A1 | Diamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-11-03 | — | — | US | disclosed |
| US-20050020645-A1 | Diamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-01-27 | — | — | US | disclosed |
| EP-1415992-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-05-06 | — | — | EP | disclosed |
| EP-1405852-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-04-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020645-A1 | Diamine derivatives | C9, C1S, C1R | GRM5 2219/4885CYP46A1 3584/4885OPRM1 468/4885 |
| US-20050245565-A1 | Diamine derivatives | C9, C1S, C1R | GRM5 2219/4885CYP46A1 3584/4885OPRM1 468/4885 |
| US-20110077266-A1 | Diamine Derivatives | F2, TFPI, F3 | GRM5 1573/4885CYP46A1 3469/4885OPRM1 3748/4885 |
| US-20110312990-A1 | Diamine Derivatives | C9, C1S, C1R | GRM5 2242/4885CYP46A1 3181/4885OPRM1 478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.